Our product platform is a transmucosal therapeutic system comprised of a drug administered through a polymeric matrix, precisely designed to target ear, nose and throat (ENT) diseases. Lyra’s product candidates are designed to provide medicine directly to diseased tissues that are not accessible with conventional therapeutic approaches.

This proprietary therapeutic consists of:

  • Long-acting medication, custom formulated for consistent topical dosing over several months
  • Polymeric matrix, with flexibility to contour to the treatment area and adapt to inflamed remodeling tissue

The therapeutic is administered by a physician in the office. It can be easily removed if desired and is biodegradable.

Lyra has a robust global portfolio of intellectual property. These patents cover all aspects of the transmucosal therapeutic system, including controlled drug release and materials science for adaptive applications in biologic environments. All intellectual property protecting the Lyra platform has been developed and is owned by the company.